Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System  by Matter-Walstra, Klazien et al.
Mz
b
t
6
1
P
d
V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 5 – 7 1
Avai lable onl ine at www.sc iencedirect .com
journal homepage: www.elsevier .com/ locate / jva lCost-Effectiveness of Maintenance Pemetrexed in Patients with
Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the
Swiss Health Care System
Klazien Matter-Walstra, PhD1,*, Markus Joerger, MD2, Ursula Kühnel3, Thomas Szucs, PhD1, Bernhard Pestalozzi, PhD, MD4,
atthias Schwenkglenks, PhD1
1Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland; 2Department of Oncology & Hematology, Cantonal Hospital, St. Gallen,
Switzerland; 3Swiss Group for Clinical Cancer Research, Bern, Switzerland; 4Department of Medical Oncology, University Hospital, Zurich, SwitzerlandA B S T R A C T€
B
2
a
n
e
s
t
e
K
l
CObjectives: A recent randomized study showed switch maintenance
with pemetrexed after nonpemetrexed-containing first-line chemo-
therapy in patients with advanced nonsmall-cell lung cancer to pro-
long overall survival by 2.8 months. We examined the cost-effective-
ness of pemetrexed in this indication, from the perspective of the Swiss
health care system, and assessed the influence of the costs of best
supportive care (BSC) on overall cost-effectiveness. Methods: A
Markovmodel was constructed based on the pemetrexedmaintenance
study, and the incremental cost-effectiveness ratio (ICER) of adding
pemetrexed until disease progression was calculated as cost per qual-
ity-adjusted life-year gained. Uncertainties concerning the costs of BSC
on the ICER were addressed. Results: The base case ICER for mainte-
nance therapy with pemetrexed plus BSC compared to BSC alone was O
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oi:10.1016/j.jval.2011.08.1737106,202 per quality-adjusted life-year gained. Varying the costs for
SC had a marked effect. Assuming a reduction of the costs for BSC by
5% in the pemetrexed arm resulted in an ICER of €47,531 per quality-
djusted life-year, which is below predefined criteria for cost effective-
ess in Switzerland. Conclusions: Switch maintenance with pem-
trexed in patients with advanced nonsquamous-cell lung cancer after
tandard first-line chemotherapy is not cost-effective. Uncertainties on
he resource use and costs for BSC have a large influence on the cost-
ffectiveness calculation and should be reported in more detail.
eywords: best supportive care, cost-effectiveness, health economics,
ung cancer, pemetrexed, maintenance treatment.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Nonsmall-cell lung cancer (NSCLC) is the leading cause of cancer-
related deaths worldwide, with more than 161,000 people in the
United States dying of the disease in 2007 [1]. The majority of
patients present with advanced disease, and the 5-year age- and
area-adjusted relative survival of all lung cancer patients in
Europe continues to be barely 11% [2]. Current guidelines recom-
mend platinum-based combination chemotherapy [2-4], as they
have shown a modest improvement of overall survival (OAS) in
several clinical studies [3-7]. Over time, improving on standard
platinum-based doublets has proven difficult and median OAS of
patients with advanced NSCLC remains between 10 and 12
months, with no substantial improvements in the past decade.
More recently, molecularly targeted drugs have been added up-
front to improve the efficacy of first-line chemotherapy in patients
with advanced NSCLC. Many of these drugs, however, have not
proven to be very useful in prolonging OAS (erlotinib and gefitinib
[8,9], and cetuximab [10]) or toxicity problems limit their use (bevaci-
umab [11,12]). In addition, prolonged first-line treatment has not
een shown to be beneficial [13-15], andmost patients are unable to
olerate long-term combination treatment after first induction
* Address correspondence to: Klazien Matter-Walstra, Institute of
1, CH-4056 Basel, Switzerland
E-mail: klazien.matter@unibas.ch.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.16,17]. Therefore, current guidelines recommend four to six cycles of
latinum-based chemotherapy for advanced NSCLC, followed by a
reatment-free interval until disease progression [2,4].
Pemetrexed is an antifolate antineoplastic agent that exerts its
ction by disrupting folate-dependent metabolism [18]. Pem-
trexed is approved in combination with cisplatin for first-line
reatment of malignant pleural mesothelioma [19], as a single
gent for second-line treatment of advanced NSCLC [20], and in
ombinationwith cisplatin for the first-line treatment of advanced
onsquamous-cell NSCLC [21]. Because of the efficacy of pem-
trexed in second-line NSCLC [20], its favorable safety profile and
ase of administration (infusion over 10minutes, given once every
weeks), a recent phase-III clinical study examined pemetrexed
s maintenance therapy in patients who had not progressed fol-
owing one of six non-pemetrexed-containing induction regimens
22]. The authors showed that pemetrexed treatment until pro-
ression prolongs progression-free survival by 1.7 months and
AS by 2.8 months [22]. This comes at the cost of substantially
igher drug expenses. Although the trial by Ciuleanu et al. [22]
sed a nonpemetrexed-containing, platinum-based first-line che-
otherapy irrespective of the tumor histotype, the platinum-pem-
trexed doublet has become standard first-line treatment in patients
rmaceutical Medicine/ECPM, University Basel, Klingelbergstrasse
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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66 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 5 – 7 1with advanced nonsquamous-cell lung cancer based on the study by
Scagliotti et al. [21].Asaconsequence, anewSpanish-ledclinical trial
will assess the benefit of pemetrexed maintenance treatment after
first-line cisplatin-pemetrexed induction chemotherapy in patients
with advanced nonsquamous-cell lung cancer [23].
The objective of our study was to examine the cost-effective-
ess of pemetrexed maintenance treatment following standard
latinum-based chemotherapy in advanced, inoperable stage IIIB
r IV nonsquamous-cell NSCLC from the perspective of the Swiss
ealth care system, and to compare it with different willingness-
o-pay (WTP) thresholds between €72,000 [24,25] (Swiss federal
ourt decision, November 23, 2010) and €150,000 [26] per QALY
ained. Secondly, the influence of the costs of best supportive care
BSC) on overall cost-effectiveness was assessed.
Materials and Methods
A Markov model was constructed to assess the cost-effectiveness
of maintenance therapy with pemetrexed plus BSC, compared to
BSC alone, in patients with advanced nonsquamous-cell lung can-
cer, based on the results of one phase III, placebo-controlled ran-
domized study by Ciuleanu et al. [22], because no other trials with
similar settingwere available. Themodel adopted a lifelong time
orizon. Costs were assessed from a Swiss health care system
erspective. Direct medical costs included pemetrexed therapy,
osts for BSC, treatment of major adverse events, and follow-up
reatment for progressive disease. Indirect costs were not consid-
red because they are irrelevant for the chosen perspective. Costs
ere based on average 2010 Swiss prices, and are reported in Eu-
os. An exchange rate of €0.72 per Swiss franc (average exchange
ate January 2010–December 2010 [27]) was used. Utilities for the
ealth states represented in the model were obtained from the
Table 1 – Unit costs and resource use.
Unit cost
Best supportive care €2555* p
Pemetrexed [40] €2.88/mg 5
Neutropenia [41,42] €5400 3
Follow-up Chemotherapy See Table 2 5
BSA, body surface area.
Fig. 1 – Markov model. Model input da* Adapted from Pompen et al. [30].literature. Costs and benefits were not discounted given the short
life expectancy of the patient population studied. Inclusion crite-
ria and details of the study treatment were previously published
[22]. In brief, 663 patients with stage IIIB or IV disease who had not
progressed during four cycles of nonpemetrexed-containing dou-
blet chemotherapy were randomly assigned in a 2:1 ratio. Patients
received pemetrexed at a dose of 500mg/m2 or placebo on day 1 of
a thrice-weekly cycle until disease progression or unacceptable
toxicity. All patients received additional BSC. The primary end-
point of the study was progression-free survival (PFS) and the sec-
ondary endpoint was OAS. The maximum length of survivor fol-
low-up was 41.5 months. For the health economic analysis, only
data for the nonsquamous-cell lung cancer patients (n  481,
based on independently central reviewed scans of patients who
had a baseline and at least one follow-up scan) were used because
pemetrexed has been approved for maintenance therapy in this
subgroup of patients. The primary endpoint of this analysis was
the incremental cost-effectiveness ratio of pemetrexed mainte-
nance therapy plus BSC, compared to BSC alone, expressed as cost
per quality-adjusted life-year (QALY) gained. Results were com-
pared with WTP thresholds of €72,000/QALY and €150,000/QALY.
One-way sensitivity analyses and probabilistic sensitivity analy-
ses (Monte Carlo simulation) were used to assess the robustness of
the results. Markov cohort and Monte Carlo analyses were per-
formed using TreeAge Pro Suite 2009 (2009, TreeAge Software Inc.,
Williamstown, MA).
Structure of the Markov model and clinical model inputs
The structure of theMarkovmodel is shown in Figure 1. Themodel
comprises three mutually exclusive health states; that is, stable/
responsive disease (entry state); disease progression; and death,
with state transitions at the end of each treatment cycle. Markov
Resource use per cycle
emetrexed arm Best supportive care arm
cle per cycle
g/m2, BSA  1.77 0
patients once per stage 0
f patients 67% of patients
r transition probabilities. See Table 3.P
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67V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 5 – 7 1cycle lengthwas 3weeks, tomatch the duration of the pemetrexed
cycles. Preference-based utility scores for stable and progressive
disease were derived from the literature. The utility assumed for
stable diseasewas 0.61 andwas calculated as themean utility over
all utilities for stable disease reported in the review by Carlson
et al. [28]. These included utilities for stable patients on oral or
ntravenous therapy and for stable patients who partially had sev-
ral adverse reactions like neutropenia, neuropathy, or nausea.
he utility of 0.61 for stable disease, with a range for sensitivity
nalysis of 0.24 to 0.73, was used for both the control and treat-
ent arm because pemetrexed therapy was not expected to affect
uality-of-life. For time in progression, a utility of 0.47 (range 0.19–
.58) [28] was used. Effectiveness data used in the model were
nferred from the data on PFS and overall survival reported in the
riginal publication. Hazards were assumed to be constant over
ime. Median time spent in each stage was used to estimate haz-
rd rates for the control arm, based on the following formula:
hazard rate  –ln(0.5)/median time in state
azard rates were converted into Markov state-transition proba-
ilities, taking into account the cycle length of 3 weeks. To model
urvival in the treatment arm, hazard rates in the control arm
ere multiplied with applicable hazard ratios (HRs). Median time
rom treatment failure to death and the corresponding HR were
stimated to fit the reported median OAS in each treatment arm
ecause they were not detailed in the original publication. With
egard to treatment-associated toxicity, the only economically rel-
vant differences in the occurrence of grade 3 or 4 adverse events
ere reported for febrile neutropenia. Therefore, only the cost of
ebrile neutropenia but no other adverse event costs were taken
nto account in the modelling.
Use of medical resources and unit costs
Medical resource use estimates were based on the study by Ciu-
leanu et al. [22]. Pemetrexed costs were calculated for a body sur-
ace area of 1.77 m2, the mean observed in an earlier Swiss lung
ancer study [29]. Because there were no data on resource use for
SC given in the Ciuleanu study, we adopted costs for BSC from a
utch study by Pompen et al. [30] (see Table 1), after adjustment
or the cycle length of our model and accounting for purchasing
ower differences between the Netherlands and Switzerland, and
nflation (2005 to  2010). Claims-based US data indicated BSC
osts for stable disease to be around 30% of the BSC costs for pro-
ressive disease [31]. This proportion was applied, while keeping
eighted average BSC costs constant at the value derived from the
utch study, which provided no such information. Costs for ad-
inistration, monitoring, andminor side-effect, were assumed to
e included in BSC costs. Management of febrile neutropenia was
iscounted separately (see Table 1). Follow-up treatments were
mplemented in the model as observed in the study by Ciuleanu
t al. [22] (see Table 2). Swiss public prices were used for pem-
trexed and anticancer drugs used post progression [32]. The exact
ndividual amount of drug was used for the costing, assuming the
ituation where surplus medication is used for another patient,
liminating the need to correct for waste. This is reasonable for
ny larger oncology ward, but might not be so for small ones.
Sensitivity analysis
To assess the influence of statistical uncertainty on key model
parameters, a series of univariate and probabilistic sensitivity
analyses were performed. In the univariate sensitivity analysis,
median progression free and overall survival with corresponding
HR, utility parameters, weighted average costs for BSC per cycle,
proportional BSC costs in cycles spent in stable vs. progressive
disease, percentage of patients with febrile neutropenia and per-T D D E G V G C C P P T B *
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68 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 5 – 7 1centage of patients with chemotherapy treatment post progres-
sion were varied as described in Table 3.
Probabilistic sensitivity analysis (second-order Monte Carlo
simulation) was based on corresponding distributions (Table 3).
Two separate analyseswere performed. In the first, the cost of BSC
per unit of time was based on the study by Pompen et al. [30] as in
the base case analysis. This estimate is believed to be the best
approximation of the Swiss situation that is currently available. In
a second analysis, the value for BSC cost per unit of time was
reduced by a factor of 10, to illustrate the potential impact of low
BSC costs as described in a health technology assessment report
for the United Kingdom by Greenhalgh et al. [33]. This wide range
reflects a knowledge gap with respect to the cost of BSC [34]. A
multiplier for the BSC cost per unit of time in the pemetrexed arm
vs. the BSC armwas included to cover the possibility of differences
in BSC-related resource use between strategies. The probability of
being cost-effective was calculated for thresholds of €72,000 [24],
and €150,000 [26]. Each sensitivity analysis was based on 1000 sets
of randomly drawn input parameters.
Additional scenarios
In the study by Ciuleanu et al. [22], patients received one to 55
cycles of pemetrexed (median 5 cycles) but the optimal duration of
pemetrexed treatment is unknown. To approximate a hypotheti-
cal situation of restricted duration of use but equal clinical effec-
tiveness, an additional scenario analysis assumed a maximum of
six cycles with pemetrexed administration. In the absence of real
cost information for BSC in Switzerland for patients in stable or
progressive disease we also performed an analysis in which BSC
costs were assumed equal in all stages of the disease.
Model validation
The model was calibrated to match the original survival data of
Ciuleanu et al. [22]. Trackers for PFS, OAS, and cycle number were
included in the model to assess for correct data fit. All model out-
puts were reviewed for plausibility, and key input parameters
were subjected to extreme variation to test for correct behavior of
the model.
Results
The clinical outputs of the Markov model matched the results of
the Ciuleanu et al. study [22] satisfactorily. Model-based median
PFS and median OAS for our model (and the original Ciuleanu
data) were 1.7 (1.8) months and 10.7 (10.3) months, respectively, in
the BSC alone arm. Corresponding results for the treatment arm
were 4.5 (4.4)months and 15.6 (15.5)months, respectively. Progres-
sion free survival probabilities and overall survival probabilities
for both arms as reported in the original paper and estimated by
the model are reported in Table 4. The base case model for a pa-
tient with a body surface area of 1.77 m2 indicated that mainte-
nance therapywith pemetrexed plus BSC (costs €99,705, effect 0.82
QALY) compared to BSC alone (costs €71,316, effect 0.56 QALY) in
patients with advanced non squamous-small-cell lung cancer
leads to a gain of 0.27 QALYs per patient at an additional cost of
€28,389. The incremental cost-effectiveness ratio (ICER) for main-
tenance therapywith pemetrexed BSC compared to BSC alone is
€106,202/QALY gained for a body surface area of 1.77 m2.
Sensitivity analysis
Univariate sensitivity analysis was performed for the base case
analysis assuming a body surface area of 1.77 m2 (Fig. 2). Varying
he utility for stable disease led to the highest ICER range, but not
o an ICER approaching the WTP threshold of €72,000 (Fig. 2). The
second most influential parameter was the multiplier for BSC
T C M P U U H H P T % B * †
69V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 5 – 7 1costs in the pemetrexed arm relative to BSC arm. Assuming the
cost of BSC per unit of time in the pemetrexed arm to be 75% of the
value for the placebo arm resulted in an ICER €47,531 per QALY
below the WTP threshold. None of the other single parameters
tested resulted in an ICER below theWTP threshold. Simultaneous
assumption of low overall BSC costs and lower BSC costs in the
pemetrexed arm resulted in an ICER, of €65,799 per QALY gained.
Reducing the number of pemetrexed cycles to a maximum of
six, assuming no impact on clinical effectiveness, resulted in an
ICER of €54,092 per QALY. Keeping costs for BSC equal for stable or
progressive disease resulted in an ICER of €143,605 per QALY
gained. Generally, sensitivity analyses showed the results to be
robust.
Probabilistic sensitivity analysis
Substantial uncertainty about themean cost of BSC led us to use a
triangular distributional assumption. To assess the influence of
this uncertainty, two probabilistic analyses were performed; one
with the costs for BSC as adopted from the study by Pompen et al.
[30] (Fig. 3), a second by a 10-fold reduction of these costs for BSC.
In the former, the probability of an ICER of pemetrexed  BSC
compared to BSC alone, of €72,000 per QALYwas 23.4% and for the
latter the probability increased to 50.6% (Fig. 3). Triangular BSC
cost distributions in the main analysis, reflecting increased pa-
Table 4 – Survival probabilities observed in the study by
Ciuleanu et al. [22] and estimated by the health
economic model.
Arm Progression-free
survival
Overall survival
Model Original
study [22]
Model Original
study [22]
Pemetrexed
6 mo 0.44 0.41 0.89 0.85
12 mo 0.19 0.18 0.67 0.60
18 mo 0.08 0.08 0.47 0.47
Placebo
6 mo 0.08 0.11 0.76 0.75
12 mo 0.01 0.05 0.47 0.41
18 mo 0 0.01 0.28 0.31Fig. 2 – Tornado diagram summarizinrameter uncertainty resulted in a wide range of possible ICER out-
comes, documenting the importance of studying the resource use
and cost implications of BSC, in different situations, in greater
detail. The results of the probabilistic sensitivity analyseswere put
in relation to different WTP values. With the highest acceptable
WTP of €150,000 per QALY, the probability that the pemetrexed
maintenance therapy is cost effective is 84.3%. This probability
increases to 99.8% when BSC costs are reduced by a factor of 10.
Discussion
Improving the outcome of patients with advanced NSCLC has
proven to be difficult, and the addition of molecularly targeted
drugs has only led to some marginal improvement of clinical out-
come [12]. The approval of pemetrexed as an exceptionally well-
tolerated drug that is given intravenously at 500 mg/m2 over 10
minutes every 3 weeks has opened the doors for prolonged main-
tenance treatment in patients not refractory to first-line platinum-
based treatment. In fact, pemetrexed treatment to progressionhas
been shown to improve PFS and OAS in a recent phase III, placebo-
controlled clinical trial [22]. Given the fact that these patients re-
ceived nonpemetrexed-containing, platinum-based first-line che-
motherapy, and the fact that pemetrexed is an active drug in the
second-line setting of advanced NSCLC, the experimental treat-
ment in the study by Ciuleanu et al. [22] might rather be seen as
early second-line treatment. Discussion on the value of mainte-
nance or early second-line treatment in patients with advanced
NSCLC has additionally been fueled by the additional costs intro-
duced by prolonged treatment. According to our model, the se-
quential addition of pemetrexed to standard platinum-based first-
line chemotherapy in patients with advanced NSCLC results in an
average gain of 0.27 QALYs per patient. This survival advantage is
associated with an average additional lifetime cost per patient of
€28,389, resulting in an average incremental cost-effectiveness ra-
tio of €106,202/QALY for maintenance therapy with pemetrexed
plus BSC compared to BSC alone. A very recent cost-effectiveness
analysis of pemetrexed as first-line maintenance therapy in this
group of patients was performed by Klein et al. [31]. According to
this study, the ICER per life-year gained was $122,371 for pem-
etrexed as compared to placebo in patients with non-squamous-
cell advanced lung cancer [31]. This is comparable to the €106,202/
QALY as found our study. A second and very similar cost-g univariate sensitivity analysis.
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70 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 5 – 7 1effectiveness analysis was performed by the UK National Institute
for Health and Clinical Excellence (NICE) from the perspective of
the British health care system [33,35]. In the latter study, the cost
f pemetrexed was £800 for a 500-mg vial, accounting for drug
osts per patient of approximately £12,076. Again, based on the
tudy results of Ciuleanu et al. [22], the ICER for pemetrexed com-
ared with best supportive care in the non-squamous-cell patient
opulationwas calculated to be £39,364 perQALY gained, based on
n incremental cost of £9,554 and an incremental QALY of 0.24
33,35]. The ICER of £39,364 per QALY as estimated by the latter
tudy corresponds to €46,449 per QALY, partially as a consequence
f lower drug costs. With equal costs for pemetrexed, the ICER
stimate would amount to €68,886 per QALY, still seen as cost-
ffective with regard to a WTP threshold of €72,000.
One disadvantage of this cost-effectiveness analysis is that it is
ased on data of only one clinical trial, as no other trials with a
imilar setting were available. Secondly, we had to rely on the
ummary results provided in the clinical trial publication [22] and
had no access to individual patients’ histories. This made it im-
possible to model, for example, situations where patients stopped
pemetrexed treatment while still stable. Although we found no
indication of relevant distortions, this may have influenced cost-
effectiveness results to a limited extent. Finally, in our cost-effec-
tiveness analysis, assumptions on the mean costs of BSC per unit
of follow-up time had a strong impact on the final ICER, as dem-
onstrated in the probabilistic sensitivity analysis (Fig. 3). Because
there were no data on the resource use and cost implications of
BSC, a base case assumption of equal costs of BSC in both treat-
ment arms was made. However, the assumption of a relatively
slight decrease of the costs of BSC by 25% in patients receiving
maintenance pemetrexed compared to patients receiving placebo
resulted in an ICER of roughly €47,531 per QALY, below our tenta-
tive cost-effectiveness threshold. Data on the costs of BSC in pa-
tients with advanced NSCLC are very limited. From an economic
evaluation perspective, it is of major interest whether or not the
Fig. 3 – Probabilistic sensitivity analysis with assumed and
adjusted life-year; WTP, willingness to pay.use of chemotherapy leads to a relative (percentage) decrease of tBSC costs compared to patients receiving BSC alone. Various stud-
ies suggest a potential for a modest reduction of BSC costs within
the range of 12% to 23%, when standard chemotherapy is admin-
istered to patients with advanced NSCLC (cisplatin/navelbine che-
motherapy vs. BSC [36], cisplatin/paclitaxel vs. BSC [37], gemcit-
abine vs. BSC [38]). Accordingly, these data provide some limited
validation of our cost estimates and assumption of a reduction of
BSC costs up to 25% in patients receiving pemetrexed mainte-
nance therapy, which resulted in an ICER per QALY of roughly
€47,531. Exact estimates of the real costs for BSC, however, are
difficult to obtain. The recent Dutch study by Pompen et al. [30]
howed yearly BSC cost of €25,222 (for hospitalizations, outpatient
visits, and diagnostic and laboratory tests, at 2005 prices) for pa-
tientswho only received first line therapy, compared to €19,420 for
patients also receiving a second-line therapy. These costs were
assumed to be realistic for the Swiss setting after adjustment for
purchasing power differences and inflation. In the absence of con-
fidence intervals for this parameter or other appropriate distribu-
tional information, we used a triangular distribution to represent
uncertainty around this parameter representing a central ten-
dency. Compared to the true distributions of most parameters, a
triangular distribution of similar width tend to underestimate the
central region of the distribution and to overestimate the tales;
that is, they can be assumed to rather overestimate than underes-
timate the impact of parameter uncertainty. The use of a range
of  50% was necessarily arbitrary. Furthermore it is unclear to
hat extent the difference in the costs of BSC for stable versus
rogressive disease described by Klein et al. [31] for the United
tates represents European or Swiss clinical practice. These issues
tress that the lack of rigorous, structured assessment of BSC data
n clinical studies is a point ofmajor concern, as has been outlined
y leading experts in palliative cancer care in a recent position
aper [39]. Theremight even be some potential for systematic bias
r error in clinical trials implementing BSC as part of the study
ld reduced best supportive care costs. QALY, quality-10-foreatment, mainly as a result of lacking standardization of the
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71V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 5 – 7 1delivery of BSC. This has some major implications for the assess-
ment of treatment costs, as has been outlined in our study.
Conclusions
The addition of maintenance pemetrexed to BSC in patients with
advanced NSCLC not progressing on standard first-line chemo-
therapy is not assumed cost-effective from the perspective of the
Swiss health care system. Assuming a large reduction of the costs
of BSC can be achieved this treatment might become cost-effec-
tive. A structured assessment of the costs for BSC is essential for
reducing the level of uncertaintywith regards to the assessment of
cost-effectiveness of anticancer therapy.
Source of financial support: This studied was funded by the
Swiss State Secretariat for Education and Research.
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